Cargando…
COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Masson SAS.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647390/ https://www.ncbi.nlm.nih.gov/pubmed/33242734 http://dx.doi.org/10.1016/j.resmer.2020.100799 |
| _version_ | 1783606901144027136 |
|---|---|
| author | Caradec, E. Mouren, D. Zrounba, M. Azoulay, L.-D. Blandin, C. Ivanoff, S. Levy, V. Brillet, P.-Y. Nunes, H. Uzunhan, Y. |
| author_facet | Caradec, E. Mouren, D. Zrounba, M. Azoulay, L.-D. Blandin, C. Ivanoff, S. Levy, V. Brillet, P.-Y. Nunes, H. Uzunhan, Y. |
| author_sort | Caradec, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7647390 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Published by Elsevier Masson SAS. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76473902020-11-09 COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib Caradec, E. Mouren, D. Zrounba, M. Azoulay, L.-D. Blandin, C. Ivanoff, S. Levy, V. Brillet, P.-Y. Nunes, H. Uzunhan, Y. Respir Med Res Letter to the Editor Published by Elsevier Masson SAS. 2021-05 2020-11-06 /pmc/articles/PMC7647390/ /pubmed/33242734 http://dx.doi.org/10.1016/j.resmer.2020.100799 Text en © 2020 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Caradec, E. Mouren, D. Zrounba, M. Azoulay, L.-D. Blandin, C. Ivanoff, S. Levy, V. Brillet, P.-Y. Nunes, H. Uzunhan, Y. COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib |
| title | COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib |
| title_full | COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib |
| title_fullStr | COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib |
| title_full_unstemmed | COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib |
| title_short | COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib |
| title_sort | covid-19 in a patient with idiopathic pulmonary fibrosis successfully treated with ruxolitinib |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647390/ https://www.ncbi.nlm.nih.gov/pubmed/33242734 http://dx.doi.org/10.1016/j.resmer.2020.100799 |
| work_keys_str_mv | AT caradece covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib AT mourend covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib AT zrounbam covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib AT azoulayld covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib AT blandinc covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib AT ivanoffs covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib AT levyv covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib AT brilletpy covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib AT nunesh covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib AT uzunhany covid19inapatientwithidiopathicpulmonaryfibrosissuccessfullytreatedwithruxolitinib |